Talphera, Inc. (TLPH)
| Market Cap | 8.97M |
| Revenue (ttm) | 27,000 |
| Net Income (ttm) | -11.64M |
| Shares Out | 20.50M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,096,736 |
| Open | 0.4242 |
| Previous Close | 0.4739 |
| Day's Range | 0.4000 - 0.4732 |
| 52-Week Range | 0.3800 - 1.1900 |
| Beta | -0.11 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+1,271.74%) |
| Earnings Date | Aug 13, 2025 |
About TLPH
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for TLPH stock is "Strong Buy" and the 12-month stock price target is $6.0.
News
Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Shakil A...
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update
Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinica...
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025
SAN MATEO, Calif. , May 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies...
Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Shakil Aslam - CMO Conference Call Participant...
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 Talphera expects the registrational NEPHRO CRRT study to be completed by the...
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million
The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 patients, of which 6 patients are already enrolled Talphera believes the NEP...
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
SAN MATEO, Calif., March 26, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi...
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week The FDA agreed to two additional protocol changes expect...
Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Shakil Aslam - Chief Medical Officer Confer...
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites Cash and inve...
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
SAN MATEO, Calif. , Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies...
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
SAN MATEO, Calif. , Sept. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi...
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites Primary endpoint in the NEPHRO CRRT study is measured ov...
Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Pal...
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at up ...
Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024
SAN MATEO, Calif. , Aug. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif. , May 20, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
Talphera to Participate at A.G.P. Virtual Healthcare Conference
SAN MATEO, Calif. , May 16, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer...
Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update
First patients at multiple sites are expected to be enrolled in the NEPHRO CRRT registrational study in Q2 2024 Dr. Shakil Aslam, an expert in renal diseases, including acute kidney injury, joins Talp...
Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024
SAN MATEO, Calif., May 2, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
Talphera, Inc. (TLPH) Q4 2023 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela ...
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
Company rebranding and corporate transformation to Talphera completed in Q1 2024 First patient enrollment in the NEPHRO CRRT registrational study expected in Q1 2024 with a projected PMA submission by...
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
SAN MATEO, Calif. , March 1, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies...